Medicare drug delays: biosimilar signals trigger 2-year price negotiation freeze

What it does

This bill delays when biologic drugs become eligible for Medicare price negotiations if a cheaper biosimilar (generic biologic) is expected to enter the market soon. Instead of negotiating prices immediately, the government waits up to 2 years after a biosimilar manufacturer publicly signals it is developing a competing product. If no biosimilar actually launches within 2 years, the original drug enters price negotiations and the biosimilar maker must pay rebates for the delay.

Why we flagged it

The bill's operative mechanism is a delay in Medicare price negotiations for biologic drugs, triggered by biosimilar development signals. The stated rationale is affordability, but the mechanism protects reference drug manufacturers' pricing power by deferring negotiation, not accelerating it.

What the text implies

• The 2-year delay is automatic upon biosimilar manufacturer disclosure—no government approval required—shifting control of negotiation timing to private companies.
• If a biosimilar never launches, the reference drug manufacturer receives a 2-year price-negotiation reprieve with no penalty beyond rebates owed only if the biosimilar fails to market.
• The bill requires biosimilar makers to confirm expected launch dates 'under penalty of perjury' but does not penalize them for missing those dates—only the reference drug manufacturer pays rebates if the biosimilar fails to launch.
• Patent litigation does not block the delay, meaning a reference drug can avoid price negotiation even while patent disputes are ongoing, potentially extending monopoly pricing.
• The rebate mechanism (75–80% of price difference) applies only if the biosimilar fails to launch; if it does launch, no rebate is owed, creating a perverse incentive for biosimilar makers to delay or abandon development.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Medicare beneficiaries and the federal government will pay higher prices for biologic drugs during the 2-year delay period. The bill prioritizes protecting reference drug manufacturers' pricing power over near-term cost control, betting that biosimilar competition will eventually arrive—but offering no guarantee and no remedy if it does not.

Who stands to gain

• biologic drug manufacturers (reference product makers)
• pharmaceutical companies with biosimilar pipelines (temporary reprieve from price competition)

Named in the bill

Centers for Medicare & Medicaid Services (CMS), Food and Drug Administration (FDA), Social Security Act Section 1192, Public Health Service Act Section 351(k), Medicare Part D, Biologic drug manufacturers, Biosimilar manufacturers

Where it stands

3 cosponsors: 2 Republicans, 1 Democrats.

• Sep 28, 2026 — Introduced · Congress.gov: “Introduced in Senate”
• Sep 28, 2026 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.